JAK2 and cancer: We hypothesized that targeted amplification of 9p24.1 in tumor genomes would result in co-amplification of PD-L1, PD-L2, and JAK2, identify a distinct molecular subtype arising in multiple cancers, and provide a candidate biomarker for patients who may benefit from immune checkpoint targeted therapies.